NCT07780669ClinicalTrials.gov
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-1)
In brief
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Phase 3624 participants sought11 sites2 countries
Categories
Registered in 1 registry
- ClinicalTrials.govNCT07780669Open this record at ClinicalTrials.govSynced 2 days ago
One study can be registered in several registries. We show it once and link every record we hold.
Trial information is shown as published by the registry, in its original language.
Interested in this study?
Sign in or create an account to register your interest and follow this study.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-08-21; recorded start 2026-08-27
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 336 other studies in this databaseCounted from the lead sponsor named in the record (GlaxoSmithKline)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre0/8
Single site, or site count not stated
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 624 participants (target), run at 11 sites, across 2 countries.
How this score is built
- Enrolment27/40
624 participants (target)
- Site count0/25
Site count not stated in the record
- Country count0/15
Country count not stated in the record
- Planned duration9/10
Planned over about 43 months
- Sponsor scale9/10
GlaxoSmithKline has led 313 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Summary
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Conditions
- Pulmonary Disease, Chronic Obstructive
Eligibility
| Sex | All |
|---|---|
| Ages | 40 Years – 80 Years |
| Healthy volunteers | No |
Eligibility as written in the registry
Eligibility in plain statements
This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.
Study design
| Study type | Interventional |
|---|---|
| Phase | Phase 3 |
| Allocation | Randomised |
| Intervention model | PARALLEL |
| Primary purpose | TREATMENT |
| Masking | QUADRUPLE (4) |
| Enrolment | 624 participants sought |
Sponsor and collaborators
- GlaxoSmithKline Sponsor
Arms and interventions
- Participants receiving GSK5784283 plus standard of careEXPERIMENTAL
- Participants receiving matching placebo plus standard of carePLACEBO_COMPARATOR
Interventions
- Drug GSK5784283
GSK5784283 will be administered.
- Drug Placebo
Placebo will be administered.
- Drug Standard of care
Standard of care will be administered.
Outcome measures
Primary outcome
Annualized rate of moderate or severe COPD Exacerbations
Moderate exacerbations are defined as clinically significant exacerbations that require treatment with oral/systemic corticosteroids and/or antibiotics. Severe exacerbations are defined as clinically significant exacerbations that require in-patient hospitalization (that is greater than or equal to \[\>=\] 24 hours) or result in death.
Time frame Up to Week 78
Secondary outcome
Change from Baseline in St. George's respiratory questionnaire (SGRQ) total score
SGRQ total score will be measured using the SGRQ for COPD (SGRQ-C). The SGRQ-C is a 14-item participant questionnaire, designed to measure health impairment by addressing the frequency of respiratory symptoms (questions 1-7) and the participant's current state (questions 8-14). The total score will be calculated on 0-100 rating scale and scores expressed as a percentage of overall impairment. Higher scores indicate greater impairment of health.
Time frame Baseline (Day 1) and up to Week 52
Secondary outcome
Change from Baseline in pre-Bronchodilator Forced expiratory volume in 1 second (FEV1)
FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration as measured by spirometry.
Time frame Baseline (Day 1) and at Week 52
Secondary outcome
Annualized rate of COPD exacerbations requiring emergency department (ED) visit or hospitalization
Annualized rate of COPD exacerbations requiring ED visit or hospitalization (For pooled analysis across studies 300629 and 300631) will be assessed.
Time frame Up to Week 78
Secondary outcome
Annualized rate of moderate/severe COPD exacerbations among participants with elevated screening blood eosinophil counts (BEC)
Annualized rate of moderate/severe COPD exacerbations among participants with elevated screening BEC (For pooled analysis across studies 300629 and 300631) will be assessed.
Time frame Up to Week 78
Secondary outcome
Time to first moderate or severe COPD exacerbation
Time to first moderate or severe exacerbation (For pooled analysis across studies 300629 and 300631) will be assessed.
Time frame Up to Week 78
Dates
| Start date | August 27, 2026 (actual) |
|---|---|
| Primary completion | July 20, 2029 (estimated) |
| Completion | March 15, 2030 (estimated) |
| First posted | August 21, 2026 (actual) |
| Last updated | November 17, 2026 |
| Results posted | Not stated in the registry record |
| Status last verified | November 2026 |
Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.
Locations
11 sites are recruiting
Japan
| Facility | City | State or region | Status |
|---|---|---|---|
| GSK Investigational Site | Fukuoka | Recruiting | |
| GSK Investigational Site | Fukuoka | Recruiting | |
| GSK Investigational Site | Ishikawa | Recruiting | |
| GSK Investigational Site | Tokyo | Recruiting |
United States
| Facility | City | State or region | Status |
|---|---|---|---|
| GSK Investigational Site | Derby | Kansas | Recruiting |
| GSK Investigational Site | Doral | Florida | Recruiting |
| GSK Investigational Site | Humble | Texas | Recruiting |
| GSK Investigational Site | Huntsville | Texas | Recruiting |
| GSK Investigational Site | Lake Charles | Louisiana | Recruiting |
| GSK Investigational Site | Staten Island | New York | Recruiting |
| GSK Investigational Site | West Jordan | Utah | Recruiting |
Study documents
No documents are linked in this registry record.
Changes over time
- November 17, 2026
Site added
2 sites added (11 total)
911
- November 12, 2026
Site added
2 sites added (9 total)
79
- November 5, 2026
Site added
5 sites added (7 total)
27
- September 9, 2026
Status changed
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- September 9, 2026
Recruitment opened
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- September 9, 2026
Site added
2 sites added (2 total)
02